Digital Ulcers in Scleroderma: Healing Now Versus Preventing the Next One
A single patient with active, unhealed digital ulcers on a background of six years of limited scleroderma. The disagreement is between treating what's open right now and treating what keeps opening.
Marisol T., a 52-year-old ceramic artist, has thrown pots for a living for two decades, and has spent the last six years managing limited cutaneous systemic sclerosis that began, as it usually does, with Raynaud's phenomenon years before any skin change appeared. Her hands are her livelihood in a literal sense, which is part of why the past year has been harder than most: three digital ulcers healed and two new ones have opened, one of them locally infected badly enough last spring to need a course of oral antibiotics. She has been on maximized amlodipine and topical nitrates the whole time, and her Raynaud's is still bad enough in cold weather that she wears gloves indoors.
Today she has two active fingertip ulcers, one with surrounding erythema that hasn't fully settled since the infection last year, and the actual therapeutic question is narrower than "treat her ulcers" — it is which agent to reach for first, and that depends on reading a specific trial's result against exactly what she needs it to do. RAPIDS-2 randomized patients with digital ulcers to bosentan or placebo and found a real, significant reduction in the formation of new ulcers, but it did not significantly accelerate healing of ulcers patients already had when the trial started — a distinction that matters directly here, since her most urgent problem right now is two ulcers that are open, not the ones that haven't formed yet. Sildenafil's own healing evidence turns out to carry the same defect, which is the part the team has to be honest about: SEDUCE, the placebo-controlled trial of sildenafil 20mg three times daily in 83 patients with systemic sclerosis, also missed its primary endpoint of time to ulcer healing (hazard ratio 1.33, p=0.18), partly because the placebo arm healed faster than expected. What it did show was a significantly lower mean number of ulcers per patient at weeks 8 and 12. So neither oral agent has clean evidence for closing an ulcer that is already open, and the honest reading is that sildenafil's advantage over bosentan here is burden and breadth, not a demonstrated healing effect. IV iloprost sits at the other end — the strongest acute evidence for healing an ulcer that's open today, at the cost of repeated infusion visits a working potter has to find time for.
In clinic, two open ulcers and a recurrence pattern
RAPIDS-2 is worth naming specifically here, not just generally: it showed bosentan reduces the formation of new digital ulcers, but it did not significantly speed healing of ulcers patients already had at enrollment. She has two open ulcers right now, one with a history of infection. Bosentan's proven benefit is aimed at a different problem than the one in front of us today. I want IV iloprost for the acute healing.
You're right that bosentan's trial evidence is about prevention, not healing — I'm not going to argue that point.
And before we settle on sildenafil as the compromise, note that its healing evidence fails on the same endpoint I just used to set bosentan aside — if that argument disqualifies bosentan for her open ulcers, it doesn't spare sildenafil either. But look at her year: three ulcers healed, two new ones now. That's a recurrence-rate problem as much as it's an acute-healing problem. Once today's ulcers are addressed — which could just as easily be wound care plus a short iloprost course — the real question is what stops ulcer number six. Treating today's healing without addressing what keeps causing new ones just resets the clock.
I don't think we have to choose between healing today and preventing tomorrow as cleanly as this is being framed. And I want to concede the obvious objection before either of you makes it: SEDUCE missed its own healing endpoint too — hazard ratio 1.33, p=0.18 — so I can't claim sildenafil closes today's ulcers on trial evidence any more than bosentan does. What SEDUCE did show was fewer ulcers per patient at eight and twelve weeks, which is a burden signal across both problems rather than a healing claim. That, plus no monthly liver-function draws and no infusion chair she has to schedule around her kiln, is the whole of my argument.
Whatever we start today, none of these three substitutes for aggressive local wound care and close infection surveillance on the ulcer that's already had one bad outcome — that part isn't optional regardless of which systemic agent wins this conversation.
Agreed: start sildenafil, continue amlodipine, begin aggressive local wound care and infection surveillance for the two active ulcers, and reassess healing at six to eight weeks. If healing is inadequate at that point, escalate to a course of IV iloprost.
Not agreed: whether bosentan should be added now in parallel, specifically for its distinct new-ulcer-prevention benefit given her one-year recurrence pattern, or held until sildenafil's own effect on that pattern can be assessed first. The rheumatologist and the vascular medicine physician genuinely differ on this, and the plan leaves it for the six-to-eight-week visit rather than deciding it today.